Filed by newsfilecorp.com News Release For Immediate Release Orgenesis Announces Management Changes White Plains, NY

Orgenesis Announces Management Changes

White Plains, NY January 7, 2013 Orgenesis Inc.

(OTCBB:ORGS) ( Orgenesis or the Company ), a development-stage company with a

novel therapeutic technology dedicated to converting a patient s own liver cells

into functioning insulin-producing cells as a treatment for diabetes, announced

today the appointment of Sav DiPasquale as President and Chief Executive

Officer. Mr. DiPasquale succeeds Jacob BenArie, who has been appointed Chief

Executive Officer of the Company s private subsidiary, Orgenesis Ltd.

Mr. DiPasquale has a strong history of executive leadership

success within the life sciences industry.

Prior to joining Orgenesis, Mr. DiPasquale worked with

GlaxoSmithKline Inc. ( GSK ), a world leading research-based pharmaceutical

company, for over 16 years in Canada. There, he served in various technology and

marketing capacities including his most recent role as Vice President, Business

Development and Corporate Planning. Among his many accomplishments at GSK, Mr.

DiPasquale established and managed a multi-million dollar business unit focused

on Type1 diabetes. He also led the creation, launch and management of a $50M GSK

venture capital fund in Canada purposed with helping to commercialize Canadian

scientific innovation from start-up and emerging life sciences companies. Mr.

DiPasquale holds a B.Sc. in computer science from the University of Toronto and

has completed the Executive Program at the Schulich School of Business.

We are very pleased to have attracted a business leader of

Sav's caliber to the Orgenesis executive team. His extensive and demonstrable

record of accomplishment in helping to commercialize new technologies in

diabetes and other therapeutic areas will be a great asset for the Company going

forward, said Orgenesis Chairperson, Vered Caplan.

Ms. Caplan continued, On behalf of the Orgenesis Board, I

would also like to thank Jacob for the many significant contributions that he

has made to the Company s success. We look forward to continuing to work closely

with him in his new senior management role.

I am driven by the promise of this opportunity to improve the

lives of people living with this disease, said Sav DiPasquale. And I am very

much looking forward to being a part of the Orgenesis team and bringing this

therapeutic technology to market.

About Orgenesis Inc.

Orgenesis (OTCBB: ORGS) is a development stage company with a

novel therapeutic technology that employs a molecular and cellular approach

directed at converting a patient's own liver cells into functional insulin

producing cells, as a treatment for diabetes. The Company believes that

converting the diabetic patient's own tissue into insulin-producing cells

overcomes the problem of donor shortage and removes the risk of transplant

rejection. If successful, this could mean the end of diabetes, as we now know

it. For more information visit: www.orgenesis.com.

Notice Regarding Forward-Looking Statements

This news release contains "forward-looking statements"

which are not purely historical. Such forward-looking statements include, among

other things, the expectations of management that our regeneration technology

can be developed as therapeutic treatment for diabetes. No assurance can be

given that any of the events anticipated by the forward-looking statements will

occur or, if they do occur, what benefits the Company will obtain from them.

Actual results could differ from those projected in any forward-looking

statements due to numerous factors. Such factors include, among others, the

inherent uncertainties associated with new projects and development stage

companies, which include, without limitation, the potential failure of

development candidates to advance through preclinical studies or demonstrate

safety and efficacy in clinical testing and the ability to pass clinical trials

so as to move on to the next phase, our ability to retain key employees and our

ability to finance development or satisfy the rigorous regulatory requirements

for new medical procedures. Competitors may develop better or cheaper

alternatives to our products. These forward-looking statements are made as of

the date of this news release, and we assume no obligation to update the

forward-looking statements, or to update the reasons why actual results could

differ from those projected in the forward-looking statements. Investors should

refer to the risk factors disclosure outlined in our periodic reports filed from

time-to-time with the Securities and Exchange Commission.

On Behalf of the Board

Vered Caplan, Chairperson